{"schema_version":"secwatch.filing_event.v1","accession":"0001472375-22-000008","form_type":"8-K","ticker":"RGPX","cik":"0001357878","company_name":"REGENEREX PHARMA, INC.","filed_at":"2022-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.102975+00:00","generated_at":"2026-06-27T17:28:50.292078+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"RegeneRex Pharma appoints Troy Thuet as COO; Dr. Lee Ori becomes Chief R&D Officer","bullets":["Troy Thuet appointed COO effective Jan 14, 2022; over 15 years of managerial and executive experience.","Dr. Lee Ori transitions from COO to Chief R&D Officer; holds PharmD from Auburn, formerly at Eli Lilly.","No departure or compensation details disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001472375-22-000008","json":"https://secwatch.observer/filing/0001472375-22-000008.json","markdown":"https://secwatch.observer/filing/0001472375-22-000008.md","text":"https://secwatch.observer/filing/0001472375-22-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357878/000147237522000008/0001472375-22-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357878/000147237522000008/ixform8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T17:28:50.292078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d5f459103","claim":"Lee Ori was appointed as Chief R & D Officer at REGENEREX PHARMA, INC..","evidence_excerpt":"He is replacing Dr. Lee Ori who has been appointed as Chief R & D Officer of the Company for the coming year.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357878/000147237522000008/0001472375-22-000008-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief R & D Officer"}],"fact_type":"executive_change"},{"claim_id":"85e8711a55","claim":"Troy Thuet was appointed as Chief Operating Officer at REGENEREX PHARMA, INC..","evidence_excerpt":"Effective January 14, 2022, Mr. Troy Thuet has been appointed to serve as Chief Operating Officer of the Company for the coming year.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357878/000147237522000008/0001472375-22-000008-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}